Core Insights - iBio, Inc. has announced promising preclinical data for IBIO-610, a potential first-in-class Activin E antibody, which shows an extended half-life in obese non-human primates and a predicted human half-life of up to 100 days, allowing for dosing as infrequently as twice a year [1][2][4] Group 1: Product Development - IBIO-610 demonstrates a half-life of 33.2 days in non-human primates, with projections indicating a human half-life of up to 100 days, which could significantly enhance patient experience by reducing dosing frequency to once every six months [1][2] - The antibody's mechanism of action is expected to provide a more comprehensive pathway modulation for obesity treatment compared to existing therapies [4] Group 2: Market Positioning - The CEO of iBio highlighted the need for durable treatment options beyond appetite control, emphasizing the potential of IBIO-610 to fill this gap in patient care [2] - The company’s AI-enabled discovery platform has successfully developed a long-acting antibody against Activin E, which could leverage the scalability of global antibody manufacturing [2] Group 3: Upcoming Presentation - The findings regarding IBIO-610 will be presented at ObesityWeek 2025, scheduled for November 4-7 in Atlanta, which may enhance visibility and interest in the product [1][2]

Core Insights - iBio, Inc. is advancing its research on the Activin E antibody, IBIO-610, which shows promise as a differentiated treatment for obesity, potentially offering fat-selective weight loss and enhancing GLP-1 therapies [2][6] - The company will present findings at two significant conferences: ObesityWeek 2025 and PEGS Europe 2025, highlighting its innovative approaches in obesity treatment [1][4] Presentation Details - At ObesityWeek 2025, Cory Schwartz will present on November 4, 2025, discussing the discovery and testing of a first-in-class Activin E antagonist antibody for obesity treatment [3] - Martin Brenner will present at PEGS Europe 2025 on November 12, 2025, focusing on the fat-selective weight loss induced by the anti-Activin E antibody in diet-induced obese mice [4] Company Overview - iBio, Inc. utilizes AI and advanced computational biology to develop biopharmaceuticals targeting cardiometabolic diseases, including obesity and cancer [4] - The company aims to transform drug discovery and accelerate development timelines through proprietary 3D modeling and innovative drug discovery platforms [4]

Core Insights - iBio, Inc. has announced promising pharmacokinetics data for IBIO-600, a long-acting anti-myostatin antibody, suggesting a potential human half-life of up to 130 days, which could position it as a best-in-class treatment for muscle preservation and weight loss [1][4][5] - The company is on track to submit a regulatory application for IBIO-600 in Q1 2026, highlighting its commitment to innovation in obesity treatment [1][5] Group 1: IBIO-600 Development - The pharmacokinetics study involved non-human primates (NHPs) and indicated a half-life of 40 to 52 days in NHPs, with human estimates ranging from 57 to 130 days [4] - The study demonstrated a dose-dependent increase in lean mass and a reduction in fat mass, with the low-dose group showing a 3.1% increase in lean mass and the high-dose group a 5.1% increase after 8 weeks [3] - The potential for a dosing schedule of once every 3 to 6 months could significantly reduce the treatment burden for patients [4][5] Group 2: Activin E Antibody - iBio has also disclosed preclinical data for a first-in-class Activin E antibody, which effectively blocks Activin E signaling and shows promise as a novel obesity treatment [5] - In an exploratory study with obese mice, the Activin E antibody as a monotherapy resulted in a 4% fat-selective weight loss and an 18% reduction in total body fat compared to placebo [5] - When combined with semaglutide, the Activin E antibody enhanced total weight loss by an additional 9%, leading to an overall weight reduction of 34% and a 72% reduction in body fat [5]